We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
ProBioGen AG, a Berlin-based contract development and manufacturing organization (CDMO) for developing and manufacturing complex therapeutic glycoproteins, has appointed Dr. Lutz Hilbrich as chief executive officer, effective June 1, 2020.